Giner-Sorian Maria, Monfà Ramon, Vives Roser, Fernández-García Silvia, Vallano Antoni, Morros Rosa
Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, España.
Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, España; Universitat Autònoma de Barcelona, Bellaterra, Cerdanyola del Vallès, Barcelona, España.
Aten Primaria. 2025 Jan 16;57(7):103205. doi: 10.1016/j.aprim.2024.103205.
To characterise patients with heart failure (HF) in Primary Health Care (PHC) and describe their socio-demographic and clinical characteristics and pharmacological treatment.
Descriptive cohort study. SITE: Information System for the Development of Research in Primary Care (SIDIAP), which captures information from the electronic health records of PHC of the Catalan Institute of Health (approximately 80% of the Catalan population).
Adults with an active diagnosis of HF between 2018 and 2022.
Sociodemographic and anthropometric variables, left ventricular ejection fraction (LVEF), New York Heart Association (NYHA), laboratory data, comorbidities, exposure to drugs for HF and other pathologies.
75,769 individuals were included; 22.7% with HF with reduced LVEF (HFrEF), 26.2% with preserved LVEF (HfpEF) and 51.2% with non-specific HF. The HfrEF group consisted mostly of men (59.5%), with a mean age of 74.8 years, and the others of women (58.8% and 54.6%, aged 78.7 and 80.6 years, respectively). LVEF was recorded in 20.3% and NYHA in 43.9% of patients. In terms of treatment, 75.3% of people with HfrEF were receiving renin-angiotensin system (RAS) drugs, 75.9% beta-blockers, 42.1% mineralocorticoid receptor antagonists, 33.6% sodium-glucose cotransporter type 2 inhibitors and 62.8% diuretics. 63% with HfpEF were receiving RAS and 68% diuretics. 61.8% with unspecified HF were receiving RAS and 67.5% diuretics.
We analysed the population with HF in PHC in Catalonia. We highlight a low registry of cardiac function, LVEF and NYHA. The frequency of drug use for HF was different between populations and differed from the recommendations.
对初级卫生保健（PHC）中的心衰（HF）患者进行特征描述，并阐述其社会人口学和临床特征以及药物治疗情况。
描述性队列研究。
初级保健研究发展信息系统（SIDIAP），该系统收集加泰罗尼亚卫生研究所初级卫生保健电子健康记录中的信息（约占加泰罗尼亚人口的80%）。
2018年至2022年间被确诊患有HF的成年人。
社会人口学和人体测量学变量、左心室射血分数（LVEF）、纽约心脏协会（NYHA）分级、实验室数据、合并症、HF及其他疾病的用药情况。
共纳入75769人；射血分数降低的心衰（HFrEF）患者占22.7%，射血分数保留的心衰（HfpEF）患者占26.2%，非特异性HF患者占51.2%。HFrEF组男性居多（59.5%），平均年龄74.8岁，其他两组女性居多（分别为58.8%和54.6%，年龄分别为78.7岁和80.6岁）。20.3%的患者记录了LVEF，43.9%的患者记录了NYHA分级。在治疗方面，75.3%的HFrEF患者接受肾素 - 血管紧张素系统（RAS）药物治疗，75.9%接受β受体阻滞剂治疗，42.1%接受盐皮质激素受体拮抗剂治疗，33.6%接受钠 - 葡萄糖协同转运蛋白2抑制剂治疗，62.8%接受利尿剂治疗。63%的HfpEF患者接受RAS药物治疗，68%接受利尿剂治疗。61.8%的非特异性HF患者接受RAS药物治疗，67.5%接受利尿剂治疗。
我们分析了加泰罗尼亚初级卫生保健中的HF人群。我们强调心脏功能、LVEF和NYHA分级的登记率较低。HF药物使用频率在不同人群中存在差异，且与推荐方案不同。
